Abstract

High levels and activity of Src kinase are common among breast cancer subtypes, and several inhibitors of the kinase are currently tested in clinical trials. Alterations in mitochondrial activity is also observed among the different types of breast cancer. Src kinase is localized in several subcellular compartments, including mitochondria where it targets several proteins to modulate the activity of the organelle. Although the subcellular localization of other oncogenes modulates the potency of known treatments, nothing is known about the specific role of intra-mitochondrial Src (mtSrc) in breast cancer. The aim of this work was to determine whether mtSrc kinase has specific impact on breast cancer cells. We first observed that activity of mtSrc is higher in breast cancer cells of the triple negative subtype. Over-expression of Src specifically targeted to mitochondria reduced mtDNA levels, mitochondrial membrane potential and cellular respiration. These alterations of mitochondrial functions led to lower cellular viability, shorter cell cycle and increased invasive capacity. Proteomic analyses revealed that mtSrc targets the mitochondrial single-stranded DNA-binding protein, a regulator of mtDNA replication. Our findings suggest that mtSrc promotes aggressiveness of breast cancer cells via phosphorylation of mitochondrial single-stranded DNA-binding protein leading to reduced mtDNA levels and mitochondrial activity. This study highlights the importance of considering the subcellular localization of Src kinase in the development of potent therapy for breast cancer.

Highlights

  • Breast cancer (BC) is characterized by various phenotype, clinical outcome, and response to treatment

  • Activity of mitochondrial Src (mtSrc) is higher in TNBC cells We first characterized the levels and activity of total Src and mtSrc in different subcellular fractions obtained from control breast epithelial cells, triple negative cells, HER2positive cells and estrogen receptor (ER)-progesterone receptor (PR)-positive cells

  • Our findings indicate that mtSrc is more active in TNBC and that overexpression of mtSrc alters the metabolic and neoplasic behavior of TNBC cells via phosphorylation of mitochondrial single-stranded DNA-binding protein (mtSSB)

Read more

Summary

Introduction

Breast cancer (BC) is characterized by various phenotype, clinical outcome, and response to treatment. BC can be classified into different subtypes based on the expression of the estrogen receptor (ER), progesterone receptor (PR) and the epidermal growth factor receptor 2 (HER2)[1]. Considering the role of metabolic pathways in cancer pathophysiology, numerous mitochondria-targeted strategies were developed for the treatment of cancer, including BC. Several cancer cells exhibit lower oxygen consumption and higher glycolysis activity[4,5] and mitochondria are crucial components in this metabolic signature. These organelles play key functions in cell physiology, including generation of ATP, reactive oxygen species (ROS), apoptosis and calcium homeostasis.

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call